# Special Issue

## Aortic Aneurysms: Vascular Remodeling and Repair 2.0

### Message from the Guest Editor

Aortic aneurysm is a multifactorial disease that is characterized by vascular remodeling due to degradation of the extracellular matrix and reduced vascular repair. It is commonly associated with atherosclerosis, hypertension, and thrombotic disorders. Present treatment options are restricted to surgical interventions such as endovascular stents or open surgical procedures that are not appropriate for all patients. Thus, there is a need for specific and effective new treatments that prevent aneurysmal growth, reduce the risk of rupture, and prevent aneurysmal extension after surgical repair. New discoveries in the field of translational biology, cell therapy, and regenerative medicine, together with new approaches to experimental design and target drug release, should accelerate the development of new therapies. This Special Issue invites both original manuscripts that describe novel findings and cutting-edge review articles that illustrate recent advances in molecular and cell biology, pathophysiology, biomarkers, novel non-surgical medications, and targeted drug delivery for aortic aneurysm.

### Guest Editor

Dr. Elena Kaschina

Max Rubner Center (MRC) for Cardiovascular Metabolic Renal Research, Institute of Pharmacology, Charité – Universitätsmedizin, Berlin, Hessische Strasse 3-4, D-10115 Berlin, Germany

### Deadline for manuscript submissions

closed (31 January 2024)

**Biomedicines**

**an Open Access Journal by MDPI**

**Impact Factor 3.9**
**CiteScore 6.8**
**Indexed in PubMed**

mdpi.com/si/135231

*Biomedicines*
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
biomedicines@mdpi.com

mdpi.com/journal/biomedicines

# Biomedicines

an Open Access Journal by MDPI

Impact Factor 3.9
CiteScore 6.8
Indexed in PubMed

mdpi.com/journal/biomedicines

MDPI

## About the Journal

### Message from the Editor-in-Chief

*Biomedicines* (ISSN 2227-9059) is an open access journal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to Biomedicines, be it original research, review articles, or developing Special Issues of current key topics.

### Editor-in-Chief

Prof. Dr. Felipe Fregni
1. Neuromodulation Center and Center for Clinical Research Learning, Spaulding Rehabilitation Hospital and Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA
2. Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA 02115, USA

### Author Benefits

**High Visibility:**

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, CAPlus / SciFinder, and other databases.

**Journal Rank:**

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Medicine (miscellaneous))

**Rapid Publication:**

manuscripts are peer-reviewed and a first decision is provided to authors approximately 17 days after submission; acceptance to publication is undertaken in 2.9 days (median values for papers published in this journal in the first half of 2025).